Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

Researchers at Karolinska Institutet have identified small molecules capable of influencing a hard-to-target receptor family linked to cancer development. The findings have been published in Nature ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full ...

New clinical evidence indicates that a widely used supplement may alter gut microbes involved in vitamin D biology and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. On the regional level, as the Human Development Index ...

A lesser-known fact is that alcohol consumption increases the risk of cancer development. Health experts from the American ...

Usually, it takes around 15–20 years for atypical cervical cells occurring from the human papillomavirus (HPV) to progress to cervical cancer. However, this can vary between individuals. Additionally, ...